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Abstract: This study aimed to evaluate the hemostatic function by thromboelastography (TEG) and determine if there was an
association between the changes in hemostatic parameters and serum cardiac troponin I (cTnI) in dogs with dilated cardiomyopathy
(DCM). DCM was diagnosed by echocardiography in 19 dogs. Ten healthy dogs were selected as controls. Myocardial injury was
confirmed by increased serum cTnI levels. Coagulation was assessed by TEG evaluating clot kinetics (reaction time [R] and kinetic time
[K]), clot strengthening (alpha [α] angle and G value), platelet function (maximum amplitude [MA] and coagulation-index [CI]), clot
stability (LY30, the percentage of lysis 30 min after MA), and global clotting times (activated partial thromboplastin time [aPTT] and
prothrombin time [PT]). Dogs with DCM had higher R and K times but lower MA, α-angle, G, and CI compared to controls (P < 0.05).
LY30 and PT did not statistically differ between groups, but the aPTT in dogs with DCM was higher than that of the controls. Serum
cTnI (median [range], ng/mL) was higher in dogs with DCM (0.25 [0.13–3.1]) than in healthy dogs (0.03 [0.01–0.06]). There was no
statistical relation between cTnI and coagulation parameters. This study showed that alterations of the coagulation status in dogs with
DCM could develop independently of serum cTnI elevations.
Key words: Dilated cardiomyopathy, thromboelastography, hemostasis, cardiac troponin I, dog

1. Introduction
Cardiological problems are one of the most common health
problems for humans but are also prevalent in elderly dogs
and cats. Dilated cardiomyopathy (DCM) is frequently
diagnosed in canine veterinary practice (1). There are
two forms of DCM: nonovert (asymptomatic, preclinical,
or occult) DCM and overt (symptomatic) DCM. In dogs
with the nonovert form, there are no noticeable clinical
symptoms, but dogs with overt DCM suffer from exercise
intolerance, coughing, abdominal distention (ascites),
and tachypnea (2,3). DCM has been diagnosed according
to the guidelines proposed by the European Society of
Veterinary Cardiology (ESVC) taskforce, which include
a scoring system for echocardiographic findings of leftventricular (LV) dilatation, reduced systolic function, and
increased sphericity of the LV (1,4).
DCM is an irreversible and progressive disease of the
heart muscles and is often complicated by heart failure,
pulmonary edema, ascites, cardiorenal syndrome, and
thromboembolic disorders (5,6). Such disorders threaten
long-term survival even if the patient receives thrombolytic
medication (7). As it is well known, vascular abnormalities,
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dilated cardiac chambers, low cardiac output, and blood
stasis can cause flow abnormalities that predispose to
hemostatic disorders in patients with heart failure (7,8).
Thus, early diagnosis of heart disease is the first step
in successfully protecting against thromboembolism
(increased clot formation or hypercoagulation) in these
patients (7).
Compared with traditional coagulation tests
such as prothrombin time (PT) and activated partial
thromboplastin time (aPTT), thromboelastography
(TEG) has been accepted as a sensitive and useful
tool for evaluating coagulation abnormalities like
hypercoagulopathy, hypocoagulapathy, and disseminated
intravascular coagulation in dogs (9,10). PT and aPTT
values indicate whether or not there are any abnormalities
in extrinsic (PT), intrinsic (aPTT), or common pathways
(both) of the coagulation cascade, but TEG has been used
to characterize the whole clotting cascade from initiation
of clot formation to fibrinolysis (9). TEG evaluates clot
kinetics (measured by reaction time [R] and kinetic time
[K]), clot strengthening (measured by alpha [α] angle
and G value), platelet function (measured by maximum
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amplitude [MA] and coagulation index [CI]), and clot
stability (measured by LY30, the percentage of lysis 30
min after MA) (11). The R-value most closely represents
the intrinsic pathway of the coagulation system whereas
K, α-angle, and MA values are related to the speed of clot
formation and platelet number and function. LY30 is a
measure of fibrinolysis and is determined primarily by the
ability of plasmin to break down the formed clot (10–13).
Although hemostasis is traditionally evaluated with
measurements of PT and aPTT in dogs with heart disease
(9), there are no published data on TEG evaluation of
hemostasis in dogs with DCM. Thus, the purpose of this
study was to evaluate hemostatic functions by kaolinactivated TEG in dogs with DCM. It is well known that
in dogs with heart disease the presence and severity
of myocardial injury is assessed by the serum level of
cardiac troponin I (cTnI), but data on how the presence of
myocardial injury affects coagulation tests are not available
yet (14–16). Therefore, we also investigated whether
there was a relationship between changes in hemostatic
parameters and the serum marker of myocardial injury
(cTnI) in dogs.
2. Materials and methods
2.1. Animals
In this study, two groups were formed: a cardiac and a
control group. For the cardiac group, 19 client-owned
dogs with DCM were selected from patient records in
a small animal hospital’s cardiology unit (Department
of Internal Medicine, Faculty of Veterinary Medicine,
Uludağ University, Bursa). Dogs with no evidence of
concurrent vector-borne pathogens (Anigen Rapid
CaniV-4 and Leishmania Ab test kits, Bionote), no
noninfectious systemic diseases (hypothyroidism,
diabetes mellitus, hyperadrenocorticism, etc.), and no
treatment during the previous week were included in the
study. Dogs were of both sexes (9 males and 10 females)
and various breeds including 4 Cavalier King Charles
spaniels, 4 Golden retrievers, 4 Anatolian shepherd dogs,
3 Labrador retrievers, 3 terriers, and one Doberman. The
dogs weighed between 12.4 and 57.5 kg and had a median
age of 10 years.
The control group consisted of 10 healthy dogs,
based on unremarkable clinicopathological evaluation
(physical examination, hematological, and biochemistry
evaluations) and seronegativity to common vector-borne
pathogens (Anigen Rapid CaniV-4 and Leishmania Ab
test kits, Bionote). The controls were of similar age, weight,
and breed as those in the cardiac group.
Animal data in this study were collected retrospectively
from hospital records, and all data consisted of the results
of diagnostic procedures that were necessary during
patient evaluations in the animal hospital.

2.2. Case selection
Only dogs with overt DCM were included in this study.
According to the ACVIM/ECVIM Consensus Classification
System (Stages A, B, C, and D), the dogs in this study were
categorized as Stage C patients, defined as patients with
past or current clinical signs of congestive heart failure.
Stage C patients also fit the criteria of Class III, in which
patients show clinical symptoms during routine activity
as described by the modified New York Heart Association
and International Small Animal Cardiac Health Council
systems. Both systems include four different stages: from
patients with asymptomatic heart disease (Class I) to
patients with heart disease causing severe symptoms at rest
(Class IV) (17).
The diagnosis of overt DCM was made primarily by
Doppler echocardiographic examination in combination
with clinical presentation and thoracic radiographic
and electrocardiographic (ECG) findings, as suggested
(1,18). Echocardiographic examinations, which were
performed by two experienced academics (ZY and/or
MK), included two-dimensional, M-mode, color flow
imaging, and spectral Doppler measurements (Caris Plus,
Esoate, Florence, Italy) with standard imaging techniques,
for which 2.5–5, 5–7.5, and 8–10 MHz phased-array
transducers were used. The dogs were not sedated during
the ultrasound examinations and were gently restrained
in right lateral recumbency on a table suitable for this
purpose.
The echocardiographic diagnosis was made using the
accepted criteria proposed by the ESVC. Briefly, dogs
with DCM showed the following: left-ventricular (LV)
dilatation; reduced systolic function (lower fractional
shortening); increased sphericity of the LV with or
without biatrial enlargement; increased E point to septal
separation (EPSS); arrhythmia, such as atrial fibrillation;
increased preejection period (PEP); and LV ejection
time (LVET) ratio. LV measurements were compared to
normal published values for specific breeds. If there was
no publication as a reference for a breed, results were
compared with breeds of similar size and weight. Each of
these echocardiographic findings was scored. Every dog
with a total score above six points was included in the
study (1).
2.3. Sample collection and measurements
Blood samples were collected before treatment from the
brachiocephalic vein into vacutainer tubes containing
K2EDTA for a complete blood count (CBC). The tubes
contained 3.2% sodium citrate (BD Vacutainer System, BD
Diagnostics, NJ, USA) for hemostatic evaluations (11). To
rule out infectious and noninfectious metabolic diseases,
CBC and serum biochemistry analyses (comprehensive
profile, Abaxis) were performed shortly after the blood
collection using automatic analyzers (HM5 and VetScan,
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Abaxis, Union City, CA, USA). Hemostatic functions were
assessed by measurements of global clotting times (aPTT
and PT) (automatic coagulation analyzer, VetScan VSpro,
Abaxis) and TEG (TEG 5000, Haemonetics, Braintree, MA,
USA), as previously described (10–12). Seven parameters
of TEG were included for this study, as selected in previous
studies (10,12,13): reaction time (R), coagulation time (K),
alpha (α) angle, maximum amplitude (MA), G value, LY30
(percentage of lysis 30 min after MA), and coagulation
index (CI).
2.4. Statistical analysis
Results were expressed as mean ± SD. The results for each
parameter were evaluated for approximate normality of
distribution by using the Kolmogorov–Smirnov statistical
test (SigmaStat, Version 3.0, GmbH, Erkrath, Germany).
For two-group comparison, data were evaluated with
Student’s t-test. P < 0.05 was considered significant.
3. Results
3.1. Patient data
A total of 19 dogs met the criteria for overt DCM. There
were five different purebred dog breeds. The median body
weight was 32 kg (mean ± SD: 40.5 ± 22.3 kg), ranging
from a 12.4 kg terrier to a 57.5 kg Turkish Anatolian sheep
dog. The median age was 10 years (range: 5–15 years).

3.2. ECG and radiological findings
The most common clinical findings were murmurs of
different severity from grade I to grade IV (19/19), weak
pulse (11/19), mucosal pallor (10/19), ascites (8/19),
jugular distension (6/19), and pulse deficit (5/19). ECG
analysis showed cardiac arrhythmias in dogs with DCM;
sinus tachycardia (9/19), atrial fibrillation (6/19), atrial or
ventricular extra systoles (5/19), and left-bundle branches
block (5/19) were the most common. Radiological
examination revealed cardiac enlargement (increased
vertebral heart scores), interstitial or alveolar pattern, and/
or pleural effusion in dogs with DCM.
3.3. Echocardiography
Cardiological examinations confirmed the diagnostic
features of overt DCM as described in Section 2.2. The
median LVDd and LVDs (interquartile range) were 4.4 cm
(3.9–4.9 cm) and 2.9 cm (2.6–3.3 cm) in the control group,
but they were 6.7 cm (5.3–7.8 cm) and 4.5 cm (1.4–7.4
cm), respectively, in the cardiac group, with a significant
difference between groups (P < 0.05–0.001) (Table). The
median and mean fractional shortening (FS) and ejection
fraction (EF) percentages were lower (P < 0.05–0.001) but
the ratio of LA diameter to Ao diastolic diameter and EPSS
value were higher (P < 0.01–0.001) in dogs with DCM
compared to those of dogs in the control group, as seen
in the Table.

Table. M-mode measurements of left ventricle and its related parameters in healthy dogs and dogs with dilated
cardiomyopathy (DCM).
Parameters

Control dogs,
mean ± SD

Dogs with DCM,
mean ± SD

P-value

RVDD, cm

0.84 ± 0.11

2.59 ± 0.91

<0.001

IVSD, cm

0.84 ± 0.11

0.91 ± 0.32

NS

LVDD, cm

4.50 ± 0.32

6.66 ± 1.04

<0.001

PWDD, cm

1.05 ± 0.19

0.86 ± 0.17

<0.05

IVSS, cm

1.23 ± 0.13

1.06 ± 0.34

NS

LVDS, cm

2.98 ± 0.28

4.11 ± 2.36

<0.05

PWSD, cm

1.18 ± 0.32

1.07 ± 0.21

NS

EF, %

69.8 ± 4.7

47.6 ± 26.7

<0.05

FS, %

32.5 ± 3.8

15.2 ± 4.9

<0.001

LA/Ao, ratio

1.12 ± 0.19

1.99 ± 0.69

<0.01

EPSS, cm

0.3 ± 0.2

0.9 ± 0.3

<0.001

RVDD: Right ventricular end diastole diameter; IVSD: interventricular septum end diastole diameter; LVDD: leftventricular diastolic distension; PWDD: posterior wall diastolic diameter; IVSS: interventricular septum end systole
diameter; LVDS: left-ventricular end-systolic diameter; PWSD: left-ventricular posterior wall systolic diameter; EF: ejection
fraction; FS: fractional shortening; LA/Ao ratio: left atrial ratio to aortic diameter; EPSS: E point to septal separation.
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3.4. Laboratory analysis
CBC and routine serum biochemistry profiles were within
reference limits in dogs with DCM (data not shown).
The serum cTnI level (ng/mL) was 0.06 (maximum), 0.01
(minimum), and 0.03 (median) in the controls and 3.1,
0.1, and 0.2 in dogs with DCM, respectively. The mean
serum cTnI level was higher (0.95 ± 1.2 ng/mL, P < 0.05)
in dogs with DCM than in the controls (0.03 ± 0.01 ng/
mL), as shown in Figure 1.
Although aPTT was higher in dogs with DCM (118 ±
36 s, P < 0.05) than in the controls (84 ± 10 s), there was
no statistical difference in PT between groups (15 ± 2 s
vs. 16 ± 1 s). TEG parameters ranged from 1.8 to 6.6 min
for R time, 0.9 to 10.7 min for K time, 10.6 to 76.3 degrees
for α-angle, 12.7 to 67.6 mm for MA, 0.7 to 10.4 for G,
0.0 to 7.1 for LY30, and –9.0 to 4.8 for CI in dogs with
DCM, as seen in Figure 2. TEG findings revealed that dogs
with DCM had significantly higher R (3.7 ± 1.9 min) and
K times (5.5 ± 4.9 min, P < 0.05) than the controls (1.5
± 0.8 min and 1.1 ± 0.4 min, respectively). MA (38 ± 23
min.), α-angle (43 ± 26 degrees), G (4.4 ± 4.1 dyn/cm2),
and CI values (–2.4 ± 6.1) were lower (P < 0.05) in dogs
with DCM compared to the control group (63 ± 9 min, 75
± 5 degrees, 9.2 ± 3.4 dyn/cm2, and 4.2 ± 1.9, respectively).
LY30 did not statistically differ between the two groups.
TEG profiles showed hypercoagulation, secondary
fibrinolysis, or platelet dysfunction (hypocoagulation)
in some cases of DCM (Figure 3). Pearson correlations
showed that there was no statistical relation between the
cTnI and coagulation parameters measured.
4. Discussion
This study has suggested for the first time that dogs with
overt DCM without any concurrent diseases might have

Serum cTnI concentration ng/mL

3.5

a changed coagulation status based on PT, aPTT, and
TEG measurements, independent of myocardial injury
(evidenced by the increase in serum cTnI level).
Our data confirmed that DCM is one of the most
common cardiac diseases in purebred, older, and giant
breeds referred to animal hospitals. In the present study,
the observed clinical (coughing, exercise intolerance,
ascites), ECG (sinus tachycardia, atrial fibrillation,
etc.), and radiological (cardiomegaly and pulmonary
patterns) findings in dogs with DCM were compatible
with those of the Stage C patient in the classification of
heart failure, as proposed by the ESVC (4). In this study,
the diagnosis of DCM was further confirmed based on
the echocardiographic findings related to geometric
(increased LV chamber size, increased EPSS, and LA/Ao)
and functional (poor FS or EF) abnormalities, along with
the cardiac arrhythmias shown in the Table and increased
serum cTnI levels represented in Figure 1 (1,12,17).
Coagulation abnormalities have been reported in
patients that show different severities of heart diseases in
human (7,19) and veterinary medicine (8,10,20), and thus
therapeutic approaches have been suggested to protect
patients from these problems (17). Coagulation activation
and related complications such as thromboembolism
were reported, especially in cats with hypertrophic
cardiomyopathy (17,21). In dogs, myxomatous mitral
valve disease can also lead to alterations of hemostasis (20).
In the present study, the observed changes in aPTT value
showed the presence of abnormalities in the intrinsic and
common pathways of the coagulation cascade (a tendency
towards a hypocoagulable state) in dogs with DCM. There
was also no statistical difference in PT values between
groups, showing that extrinsic system abnormalities were
not possible in these dogs.

*

3.0
2.5
2.0
1.5
1.0
0.5
0.0
Healthy Dogs

Dogs with DCM

Figure 1. Comparison of serum cardiac troponin I (cTnI) between control (healthy) dogs and dogs with dilated cardiomyopathy
(DCM). Data are presented as boxes and whiskers. Each box includes the interquartile range, whereas the line within a box represents
the median; the whiskers represent the range and extend to a maximum of 1.5 times the interquartile range. *P < 0.05, as compared to
healthy controls.
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Figure 2. Comparison of reaction time (R), kinetic time (K), alpha angle, maximum amplitude (MA), G value, and LY30 between
control (healthy) dogs and dogs with dilated cardiomyopathy (DCM). Data are presented as boxes and whiskers. Each box includes the
interquartile range, whereas the line within a box represents the median; the whiskers represent the range and extend to a maximum of
1.5 times the interquartile range. *P < 0.05, as compared to healthy controls.
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Figure 3. Some individual data of TEG profiles in dogs with dilated cardiomyopathy indicating normal coagulation (A), hypercoagulation
due to shortened R and K times and increased MA and alpha angle (B), and hypocoagulation states or platelet dysfunction due to
reduced MA and alpha angle (C and D).

Since PT and aPTT values are reported to have
limited diagnostic accuracy for hypercoagulation,
TEG has been suggested as an alternative diagnostic
tool that has higher sensitivity and specificity to show
hypercoagulation and hypocoagulation when compared
to traditional coagulation assays (PT, aPTT, or d-dimer)
(9,11). In the present study, the observed increase in mean
R and K times, as well as decreased MA, α-angle, G, and
CI values, as compared with the data of control dogs as
shown in Figure 2, seem related to hypocoagulation
(platelet dysfunction and secondary fibrinolysis) in dogs
with DCM. The state of hypocoagulation may be related
with platelet dysfunction rather than a decrease in serum
proteins of coagulation and thrombocytopenia in dogs
suffering from heart diseases. On the other hand, that
there was no statistically significant change in LY30 (a
TEG parameter indicating fibrinolysis) between groups
did not support a hypocoagulation status in these patients.
Therefore, further and more detailed studies are needed to
confirm these observations in dogs with DCM.
Individual data of some dogs studied were consistent
with the hypercoagulation state represented in Figure 3.

This observation is compatible with those of previous
studies indicating the presence of hypercoagulation or
a prothrombotic state during heart diseases in humans
(7,18,22) and dogs (23). Previous studies reported
hypercoagulable results based on TEG measurements in
dogs with parvoviral enteritis (24), endotoxemia (11),
neoplasia (25), and immune-mediated hemolytic anemia
(26). A hypercoagulable state in dogs with DCM may be
due to increased catecholamine and cytokine responses,
upregulation of the renin–angiotensin–aldosterone
system, or increased P-selection expression during heart
failure (27–29).
In this study, myocardial damage was confirmed by
observed increases in serum cTnI values, as compared
to controls, like in previous studies (14–16). There is a
lack of information on how the presence and severity of
myocardial injury affects the coagulation status in patients
with advanced heart diseases. The results of the Pearson
correlations suggested that cTnI and TEG parameters did
change independently in the course of heart disease in
dogs. There was positive correlation between aPTT and
R and K times, suggesting that aPTT value may represent
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a quality of clot kinetics in addition to evaluation of the
intrinsic and common pathways of coagulation (9).
In conclusion, the present study shows, for the first time
according to TEG measurements, that individual results
were commonly compatible with a hypercoagulation
rather than hypocoagulation state in dogs with DCM.
Clinicians should keep in mind that coagulation status

is a dynamic process and might change to a hyper- or
hypocoagulation state in dogs with DCM, regardless of
myocardial injury. Thrombolytic therapy in patients with
a hypocoagulation state due to heart problems would be
contraindicated. Thus, TEG evaluation may be necessary
before treatment to determine the trend of coagulation in
canine veterinary practice.
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